Hopp til innhold
NHI.no
Annonse

Dermatomyositt: Prognose

Innhold i artikkelen

Uten behandling blir sykdommen gradvis verre og verre. Moderne behandling gjør imidlertid at de aller fleste blir bedre. Full helbredelse forventes hos 50 prosent av pasientene. Cirka 20 prosent kan ha vedvarende plager gjennom flere år.

Annonse

Moderne behandling har redusert dødeligheten fra nær 50 prosent til mindre enn 10 prosent.

Barn med dermatomyositt har bedre prognose enn voksne.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Dermatomyositt . Referanselisten for dette dokumentet vises nedenfor

  1. Femia AN. Dermatomyositis. Medscape, last updated Jul 21, 2021.
  2. Vleugels RA. Clinical manifestations of dermatomyositis and polymyositis in adults. UpToDate, last updated Oct 18, 2021. UpToDate
  3. Andersson H, Bakland G, Dahl-Hofseth B, Aga Ljoså M-K. Inflammatoriske myopatier. Veileder. Norsk Revmatologisk Forening. Dato publisert 14.10.2021. norskrevmatologi.no
  4. Chu LL, Rohekar G. Dermatomyositis. CMAJ. 2019;191(12):E340. PubMed
  5. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies. The Lancet Neurology. 2018;17(9):816-28. PubMed
  6. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060. PubMed
  7. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30. PubMed
  8. Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: Current concepts. Clin Dermatol. 2018 Jul - Aug. 36 (4):450-458.
  9. Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, et al. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. Journal of the American Academy of Dermatology, published November 17, 2018. doi:10.1016/j.jaad.2018.11.023 DOI
  10. Tomasova Studynkova J, Charvat F, Jarosova K, et al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford). 2007;46:1174-1179. PubMed
  11. Amato AA, Vleugels RA. Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults. UpToDate, last updated Feb 26, 2021. UpToDate
  12. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis and rheumatism. 2007;57(5):768-77. PubMed
  13. Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022. pmid:36198179 PubMed
  14. Carruthers EC, Choi HK, Sayre EC, et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2014 Sep 5. pii: annrheumdis-2014-205800
  15. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009 Dec. 36(12):2704-10.
  16. Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmunity reviews. 2014;13(10):1048-54. PubMed
Annonse
Annonse